BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 20074463)

  • 1. Acute rejection features in dual kidney transplant recipients from elderly donors: comparison of calcineurin inhibitor-based and calcineurin inhibitor-free immunosuppressive protocols.
    Aiello FB; Furian L; Marino S; Marchini F; Cardillo M; De Fazio N; Rigotti P; Valente M
    Int J Immunopathol Pharmacol; 2009; 22(4):1001-7. PubMed ID: 20074463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
    Sayin B; Canver B; Gurlek Demirci B; Colak T; Ozdemir BH; Haberal M
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
    Sadaka B; Ejaz NS; Shields AR; Cardi MA; Wadih G; Witte D; Abu Jawdeh BG; Alloway RR; Woodle ES
    Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
    Shimizu T; Tanabe T; Omoto K; Ishida H; Tanabe K
    Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor-free immunosuppression in dual kidney transplantation from elderly donors.
    Furian L; Baldan N; Margani G; Ekser B; Silvestre C; Marchini F; Bonfante L; Rossi B; Valente ML; Rigotti P
    Clin Transplant; 2007; 21(1):57-62. PubMed ID: 17302592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Immunosuppressive Regimens Among Living-Donor Renal Transplant Recipients.
    Bakr MA; Nagib AM; Gheith OA; Hamdy AF; Refaie AF; Donia AF; Neamatalla AH; Eldahshan KF; Denewar AA; Abbas MH; Mostafa AI; Ghoneim MA
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):16-23. PubMed ID: 28260425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients.
    Banasik M; Boratyńska M; Nowakowska B; Haloń A; Kościelska-Kasprzak K; Drulis-Fajdasz D; Patrzałek D; Weyde W; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2718-20. PubMed ID: 18021967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritubular capillary C4d staining in late acute renal allograft rejection--is it relevant?
    Satoskar AA; Lehman AM; Nadasdy GM; Sedmak DD; Pesavento TE; Henry ML; Pelletier RP; Ferguson RM; Nadasdy T
    Clin Transplant; 2008; 22(1):61-7. PubMed ID: 18217907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of rejections in HIV-positive recipients of kidney transplantation: a single center prospective trial.
    Malat GE; Ranganna KM; Sikalas N; Liu L; Jindal RM; Doyle A
    Transplantation; 2012 Nov; 94(10):1020-4. PubMed ID: 23169224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients.
    Djamali A; Muth BL; Ellis TM; Mohamed M; Fernandez LA; Miller KM; Bellingham JM; Odorico JS; Mezrich JD; Pirsch JD; D'Alessandro TM; Vidyasagar V; Hofmann RM; Torrealba JR; Kaufman DB; Foley DP
    Kidney Int; 2013 Jun; 83(6):1185-92. PubMed ID: 23447068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive regimen and interstitial fibrosis and tubules atrophy at 12 months postrenal transplant.
    Gelens MA; Steegh FM; van Hooff JP; van Suylen RJ; Nieman FH; van Heurn LW; Peutz-Kootstra CJ; Christiaans MH
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):1010-7. PubMed ID: 22490875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection.
    Sun Q; Cheng Z; Cheng D; Chen J; Ji S; Wen J; Zheng C; Liu Z
    Kidney Int; 2011 Mar; 79(6):655-662. PubMed ID: 20980975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function.
    Weir MR; Blahut S; Drachenburg C; Young C; Papademitriou J; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Am J Nephrol; 2004; 24(4):379-86. PubMed ID: 15237243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.